However, the function of these immune cells can be hindered by the engagement of immune checkpoint molecules such as PD‐L1/PD1 and B7‐H4.[3] While the immune checkpoint inhibitors (ICIs) can unleash and sustain the T‐cell response against the tumor, limited fraction of TNBC patients with PD‐L1 expression and inherent resistance is a barrier affecting its therapeutic effectiveness.[36] Therefore, identifying the impact of B7‐H4 and its proteolytic regulatory mechanisms in TNBC offers a potential targeting strategy to sensitize immune‐cold TNBC tumors to ICIs and ADCs. This evidence concerns the gene VTCN1 and neoplasm.